The Initial Experience of Eslicarbazepine in Children at Three Canadian Tertiary Pediatric Care Centers
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Eslicarbazepine (ESL) demonstrates good retention and tolerability in pediatric patients with drug-resistant epilepsy. Real-world data show non-serious adverse effects, supporting its long-term use in children.
Area Of Science
- Neurology
- Pharmacology
Background
- Eslicarbazepine (ESL) is a third-generation antiseizure medication.
- It targets voltage-gated sodium channels to manage focal-onset seizures.
Purpose Of The Study
- To evaluate the real-world retention rate, efficacy, and tolerability of eslicarbazepine in Canadian children.
- To assess ESL's effectiveness in pediatric patients with epilepsy soon after its availability.
Main Methods
- Retrospective review of patients prescribed eslicarbazepine from September 2017 to June 2020.
- Inclusion criteria: at least 3 years of follow-up data from 3 Canadian pediatric tertiary care centers.
Main Results
- Fifty pediatric patients initiated on eslicarbazepine (mean age 12.4 years).
- 48% experienced non-serious adverse effects (dizziness, drowsiness); none were serious.
- 70% retention rate; 30% achieved ≥50% seizure reduction, with 2 becoming seizure-free.
Conclusions
- Eslicarbazepine shows long-term effectiveness and tolerability in children with drug-resistant epilepsy.
- Adverse effects were infrequent and generally non-serious, rarely leading to discontinuation.
- Real-world data support ESL's utility in pediatric epilepsy management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.